Mita, N.; Iwashita, T.; Uemura, S.; Yoshida, K.; Iwasa, Y.; Ando, N.; Iwata, K.; Okuno, M.; Mukai, T.; Shimizu, M.
Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure. J. Clin. Med. 2019, 8, 761.
https://doi.org/10.3390/jcm8060761
AMA Style
Mita N, Iwashita T, Uemura S, Yoshida K, Iwasa Y, Ando N, Iwata K, Okuno M, Mukai T, Shimizu M.
Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure. Journal of Clinical Medicine. 2019; 8(6):761.
https://doi.org/10.3390/jcm8060761
Chicago/Turabian Style
Mita, Naoki, Takuji Iwashita, Shinya Uemura, Kensaku Yoshida, Yuhei Iwasa, Nobuhiro Ando, Keisuke Iwata, Mitsuru Okuno, Tsuyoshi Mukai, and Masahito Shimizu.
2019. "Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure" Journal of Clinical Medicine 8, no. 6: 761.
https://doi.org/10.3390/jcm8060761
APA Style
Mita, N., Iwashita, T., Uemura, S., Yoshida, K., Iwasa, Y., Ando, N., Iwata, K., Okuno, M., Mukai, T., & Shimizu, M.
(2019). Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure. Journal of Clinical Medicine, 8(6), 761.
https://doi.org/10.3390/jcm8060761
